Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision
Open accessThe DOI matches its Crossref record; 183 of the 192 references it cites were found in a registry or an index; 48 of the 182 sources its claims cite were checked for support.
Abstract
Fungal diseases kill more than 1.5 million and affect over a billion people. However, they are still a neglected topic by public health authorities even though most deaths from fungal diseases are avoidable. Serious fungal infections occur as a consequence of other health problems including asthma, AIDS, cancer, organ transplantation and corticosteroid therapies. Early accurate diagnosis allows prompt antifungal therapy; however this is often delayed or unavailable leading to death, serious chronic illness or blindness. Recent global estimates have found 3,000,000 cases of chronic pulmonary aspergillosis, ~223,100 cases of cryptococcal meningitis complicating HIV/AIDS, ~700,000 cases of invasive candidiasis, ~500,000 cases of Pneumocystis jirovecii pneumonia, ~250,000 cases of invasive aspergillosis, ~100,000 cases of disseminated histoplasmosis, over 10,000,000 cases of fungal asthma and ~1,000,000 cases of fungal keratitis occur annually. Since 2013, the Leading International Fungal Education (LIFE) portal has facilitated the estimation of the burden of serious fungal infections country by country for over 5.7 billion people (>80% of the world’s population). These studies have shown differences in the global burden between countries, within regions of the same country and between at risk populations. Here we interrogate the accuracy of these fungal infection burden estimates in the 43 published papers within the LIFE initiative.
Overview
CoChat Summary
TL;DR
This review interrogates the accuracy of global and multi-national estimates of serious fungal disease burden generated through the Leading International Fungal Education (LIFE) initiative. It summarizes estimates from 43 published country reports and highlights wide variation, data gaps, and likely underestimation of fungal disease burden.
Key findings
- Recent global estimates include 3,000,000 cases of chronic pulmonary aspergillosis, ~223,100 cases of cryptococcal meningitis complicating HIV/AIDS, ~700,000 cases of invasive candidiasis, ~500,000 cases of *Pneumocystis jirovecii* pneumonia, ~250,000 cases of invasive aspergillosis, ~100,000 cases of disseminated histoplasmosis, over 10,000,000 cases of fungal asthma, and ~1,000,000 cases of fungal keratitis annually.
- Across LIFE country papers, candidaemia burden was 159,253 cases in 39 countries, invasive aspergillosis was 81,927 cases in 40 countries, and *Pneumocystis jirovecii* pneumonia was 133,487 cases in 40 papers; the highest candidaemia prevalence was reported in Pakistan (38,795 cases, 21 per 100,000).
- Chronic pulmonary aspergillosis estimates were highest in India (209,147) and Nigeria (120,753), with an overall incidence of 22 cases per 100,000 (14.2–30.59 95% CI); ABPA was estimated at 3,550,157 cases and SAFS at 4,125,428 cases across 43 countries.
- Tinea capitis was estimated at 21,073,423 cases in just 16 countries, with Nigeria alone accounting for 15,581,400 cases; global recurrent vulvovaginal candidiasis prevalence was estimated at about 134,000,000 cases.
Methods
- Narrative review of 43 published papers within the LIFE initiative, covering >2000 million people (29% of the world population), with the LIFE portal having facilitated estimates for over 5.7 billion people (>80% of the world’s population).
- The paper describes how country-level burden estimates were derived for specific fungal diseases, using published epidemiological data, modelling assumptions, and at-risk population denominators.
- Main analysis is descriptive and comparative: it aggregates country estimates, examines differences by region, country, and at-risk group, and discusses strengths and weaknesses of the estimation methods.
Limitations
- The paper states that a precise estimate of global prevalence and incidence for each fungal infection remains unknown, and data are scanty in most countries, especially in the developing world.
- It states that knowledge is impaired by lack of regular national surveillance, no obligatory reporting of fungal diseases, poor clinician suspicion outside specialised units, poor diagnostic test performance, and few well-designed published studies; estimates are not intended as a substitute for high-quality epidemiological study or comprehensive surveillance.
- It also states that comparisons across countries are difficult because recent local epidemiological data were available for only some countries, data quality varies, not all institutions report infections, and many low- and low-middle-income countries lack blood culture systems; the text makes evident that country estimates rely on heterogeneous assumptions and uniform rates in places, such as 5 per 100,000 for candidaemia when local data were unavailable and 6% for recurrent vulvovaginal candidiasis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
33 Valid · 8 Not valid · 70 Not checked · 75 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“In particular, resistance to fluconazole is common [30,43,44]”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
What the sources say
- Not checked — no full text of the sourcecites [30] Arendrup M.C. Candida and Candidaemia: Susceptibility and Epidemiology Dan. Med. J. 2013 60 1 32 24192246
- Disputedcites [43] Hii I.M. Chang H.L. Lin L.C. Lee Y.L. Liu Y.M. Liu C.E. Chen C.H. Cheng Y.R. Chang C.Y. Changing epidemiology of candidemia in a medical center in middle Taiwan J. Microbiol. Immunol. Infect. 2015 48 306 315 10.1016/j.jmii.2013.08.017 24113067 sourceExperimental — accuracy not yet measured
The Discussion reports an overall fluconazole resistance rate of 4.95% among the clinical Candida isolates, contrary to the unqualified claim that resistance is common. The Antifungal susceptibility section distinguishes resistance from reduced susceptibility: only 4.4% of C. glabrata isolates were resistant, although 66.7% were dose-dependent susceptible. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Supportedcites [44] Al Thaqafi A.H.O. Farahat F.M. Al Harbi M.I. Al Amri A.F.W. Perfect J.R. Predictors and outcomes of Candida bloodstream infection: Eight-year surveillance, western Saudi Arabia Int. J. Infect. Dis. 2014 21 5 9 10.1016/j.ijid.2013.12.012 24468816 source
The Discussion describes a high level of fluconazole resistance as alarming. The Results report low in vitro susceptibility among Candida bloodstream isolates in the hospital studied, supporting the claim in that setting. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Modelling with existing outcome data shows that mortality associated with these priority fungal diseases concurrently with the Joint United Nations Program on HIV/AIDS (UNAIDS) 90-90-90 campaign could save over 1.6 million lives of persons living with HIV globally over the next five years [2].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 1. Introduction
What the sources say
- Supportedcites [2] Denning D.W. Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500,000 by 2020 to be realized Philos. Trans. R. Soc. B 2016 371 10.1098/rstb.2015.0468 28080991 PMC5095544 source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The burden of infectious (all-cause, including fungal) keratitis in Mexico was estimated based on the prevalence of reported in China (0.148%) [150].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.6. Fungal Keratitis
What the sources say
- Supportedcites [150] Cao J. Yang Y. Yang W. Wu R. Xiao X. Yuan J. Xing Y. Tan X. Prevalence of infectious keratitis in Central China BMC Ophthalmol. 2014 14 1 6 10.1186/1471-2415-14-43 24690368 PMC3976152 source
The Abstract Results report an infectious keratitis prevalence of 0.148% in Central China and separately include fungal keratitis among its causes. The Mexico estimate is the citing authors’ use of that figure, not a result attributed to this source. (LLM, conf=0.92)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Since 2013, the Leading International Fungal Education (LIFE) portal has facilitated the estimation of the burden of serious fungal infections country by country for over 5.7 billion people (>80% of the world’s population).”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > Abstract
What the sources say
- Partly supportedcites [14] Denning D.W. Calling upon all public health mycologists Eur. J. Clin. Microbiol. Infect. Dis. 2017 36 923 924 10.1007/s10096-017-2909-8 28150046 sourceExperimental — accuracy not yet measured
The paper describes systematic country-by-country estimates of serious fungal infections and links to the LIFE site for completed estimates (p. 1). It does not state that the portal facilitated this work since 2013 or that the estimates covered over 5.7 billion people (>80% of the world’s population); its stated figure of 883 million people refers only to the current 14-country series (p. 1). (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“HIV/AIDS pandemic, tuberculosis, chronic obstructive pulmonary disease (COPD), asthma and the increasing incidence of cancers are the major drivers of fungal infections in both developed and developing countries globally [1,2,3,4,5,6].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [1] Brown G.D. Denning D.W. Gow N.A.R. Levitz S.M. Netea M.G. White T.C. Hidden Killers: Human Fungal Infections Sci. Transl. Med. 2012 4 1 9 10.1126/scitranslmed.3004404 23253612 source
- Partly supportedcites [2] Denning D.W. Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500,000 by 2020 to be realized Philos. Trans. R. Soc. B 2016 371 10.1098/rstb.2015.0468 28080991 PMC5095544 sourceExperimental — accuracy not yet measured
The Introduction identifies major fungal diseases complicating HIV, and the section on chronic pulmonary aspergillosis complicating tuberculosis in HIV-positive patients names TB and COPD as underlying pulmonary disorders (page unavailable). The paper does not identify asthma or increasing cancer incidence as drivers, nor does it establish that the listed conditions are the major drivers of fungal infections globally across developed and developing countries. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [3] Armstrong-James D. Meintjes G. Brown G.D. A neglected epidemic: Fungal infections in HIV/AIDS Trends Microbiol. 2014 22 120 127 10.1016/j.tim.2014.01.001 24530175 source
- Not checked — no full text of the sourcecites [4] Guinea J. Torres-Narbona M. Gijón P. Muñoz P. Pozo F. Peláez T. de Miguel J. Bouza E. Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: Incidence, risk factors, and outcome Clin. Microbiol. Infect. 2010 16 870 877 10.1111/j.1469-0691.2009.03015.x 19906275 source
- Not checked — no full text of the sourcecites [5] Marr K.A. Carter R.A. Boeckh M. Martin P. Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: Changes in epidemiology and risk factors Blood 2002 100 4358 4366 10.1182/blood-2002-05-1496 12393425 source
- Not checked — no full text of the sourcecites [6] Limper A.H. Adenis A. Le T. Harrison T.S. Fungal infections in HIV/AIDS Lancet Infect. Dis. 2017 10.1016/S1473-3099(17)30303-1 28774701 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
52 more claims · 6 with their cited sources checked
Create a free account to see all 186 claims and to verify the 39 references still open.
- Probably not a substantial claim. 80
- It may state two separate claims as one. 82
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although the target organ of A. fumigatus is the lungs, Aspergillus is known to be angiotropic and has an affinity for host vasculature. As growing hyphae penetrate pulmonary tissues, they can invade the endothelial lining of nearby blood vessels and break off into circulation, causing sepsis and dissemination accompanied by thrombosis, hemorrhagic infarction and invasion of distant organs [8, 164”
From Mechanisms of fungal dissemination (2021) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fungal pathogens are responsible for at least 13 million infections and 1.5 million deaths globally per year, primarily in those with some compromised immune function [1].”
From Prevalence and Healthcare Burden of Fungal Infections in the United States, 2018 (2022) · cites this paper as [1]
Experimental — accuracy not yet measuredIn the citing paper
“In healthy individuals, these conidia are rapidly cleared, but in the case of immunocompromised patients, conidia can germinate and develop filamentous hyphae [1, 166]. This fungal growth can result in invasive aspergillosis: a severe and aggressive fungal disease characterized by tissue damage, necrosis and hypoxia [8, 164, 167].”
From Mechanisms of fungal dissemination (2021) · cites this paper as [8]
In the citing paper
“Candida albicans the primary species responsible for mucosal disease”
From Acquisition of cross-azole tolerance and aneuploidy in Candida albicans strains evolved to posaconazole (2022) · cites this paper as Bongomin et al. 2017
In the citing paper
“Deep-seated candidiasis, arising from direct inoculation or hematogenous dissemination of Candida into normally sterile body sites, is often difficult to diagnose and may affect a population as large as that of candidemia [4,5,6].”
From Treatment of Invasive Candidiasis: A Narrative Review (2018) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“28,447 [2.5% of 1,136,092] (62 per 100,000) patients with ABPA”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“37,491 [3.33% of 1,136,092] (37.5 per 100,000) with severe asthma with fungal sensitisation (SAFS)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“Average incidence is 154 cases per 100,000 (SD ± 654)”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“the highest incidence rates reported in United Kingdom (654 per 100,000)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
“The total burden of candidaemia is 159,253 cases across these 39 countries with available data.”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
“Europe (n = 1 country, 420,549 cases)”
Citations
Cites
Vos, T., Flaxman, A. D., Naghavi, M., Lozano, R., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., Aboyans, V., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61729-2 · Cited by 8,291
Wang, H., Naghavi, M., Allen, C., Barber, R. M., Bhutta, Z. A., Carter, A., Casey, D. C., Charlson, F. J., Chen, A. Z., Coates, M. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31012-1 · Cited by 6,596
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496 · cited 1×
“Candidaemia is the most common form of invasive candidiasis associated with an unacceptably high mortality rates in excess of 40% even with the introduction of newer antifungal agents [30,32,33].”
BackgroundHidden Killers: Human Fungal Infections
Brown, G. D., Denning, D. W., Gow, N. A. R., Levitz, S. M., Netea, M. G., & White, T. C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004404 · Cited by 4,284 · cited 1×
“Pneumocystis jirovecii pneumonia is emerging as a leading cause of infection in HIV/AIDS patients [1].”
BackgroundSelf-citationGlobal burden of disease of HIV-associated cryptococcal meningitis: an updated analysis
Rajasingham, R., Smith, R. M., Park, B. J., Jarvis, J. N., Govender, N. P., Chiller, T. M., Denning, D. W., Loyse, A., & Boulware, D. R. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30243-8 · Cited by 1,861 · cited 1×
“[8], Fungal Infection Trust [12], Global Action Fund for Fungal Infection (GAFFI) Roadmap [9], and van de Sande [13].”
BackgroundSelf-citationGlobal asthma prevalence in adults: findings from the cross-sectional world health survey
To, T., Stanojevic, S., Moores, G., Gershon, A. S., Bateman, E. D., Cruz, A. A., & Boulet, L.-P. (2012) · BMC Public Health · doi:10.1186/1471-2458-12-204 · Cited by 1,521 · cited 1×
“6% respectively among individuals aged 18 to 45 years [142].”
BackgroundKullberg, B. J., & Arendrup, M. C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1315399 · Cited by 1,315 · cited 1×
“Candidaemia is the most common form of invasive candidiasis associated with an unacceptably high mortality rates in excess of 40% even with the introduction of newer antifungal agents [30,32,33].”
BackgroundSobel, J. D. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60917-9 · Cited by 1,270
Marr, K. A., Carter, R. A., Boeckh, M., Martin, P., & Corey, L. (2002) · Blood · doi:10.1182/blood-2002-05-1496 · Cited by 957
(2006) · PubMed · Cited by 906
Research works printed but not linked: 6
- Denning D.W. Global fungal Burden Mycoses 2013 56 13
- The Fungal Infection Trust How common are fungal diseases? Proceedings of the Fungal Research Trust 20th Anniversary Meeting London, UK 18 June 2011 updated August 2017, London, UK 2017 Available online: http://www.fungalinfectiontrust.org/wp-content/uploads/2015/12/How-Common-are-Fungal-Diseases-v12.2.pdf (accessed on 12 September 2017)
- Jayasekera P.I. Denning D. Perera P. Fernando A. Kudavidanage S. The burden of serious fungal infections in Sri Lanka Mycoses 2013 56 103
- Beardsley J. Denning D. Chau N. Crump J. Day J. Estimating the burden of fungal diseases in Vietnam Eur. Conf. Clin. Microbiol. Infect. Dis. Published Online First: 2014 Available online: http://eccmid.meetingxpert.net/ECCMID_699/poster_108496/program.aspx/anchor108496 (accessed on 31 August 2017)
- Gugnani H.C. Denning D.W. Rahim R. Sadat A. Belal M. Mahbub M.S. Medina N. Samayoa B. Lau-Bonilla D. Denning D.W. Burden of serious fungal infections in Bangladesh Eur. J. Clin. Microbiol. Infect. Dis. 2017 36 965 969 10.1007/s10096-017-2921-z 28161744 · DOI · Paper page
- Samayoa B. Isern V. Serra L. Rivera B.E. Nikiforov M. Arathoon E. Samayoa C. Vallès X. Prieto L. Álvarez C. Preliminary results of a prospective cohort of HIV+ patients in Guatemala Proceedings of the XVIII International AIDS Conference Vienna, Austria 18–23 July 2010
Cited by
Items 701–800 of 2,932
Epidemiología de las micosis invasoras: un paisaje en continuo cambio
Quindós, G. (2018) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2018.07.002 · Cited by 28
Li, Y., Shan, M., Yan, M., Xu, Y., Wang, Y., Chen, Y., Gu, B., Li, H., & Zhu, Z. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.05.165 · Cited by 24
Kakande, T., Batunge, Y., Eilu, E., Shabohurira, A., Abimana, J. B., Akinola, S. A., Muhwezi, R., Adam, A. S., Onkoba, S. K., Aliero, A. A., et al. (2019) · Dermatology Research and Practice · doi:10.1155/2019/9328621 · Cited by 22
“[5], the global burden of cutaneous infection was estimated to be ∼1001000, 000.”
BackgroundCarrizo, S. L., Zampini, I. C., Sayago, J. E., Simirgiotis, M. J., Bórquez, J., Cuello, A. S., & Isla, M. I. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.112553 · Cited by 26
Hoffman, J. J. S. L., Yadav, R., Sanyam, S. D., et al. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-038066 · Cited by 21
Krylov, V. B., Solovev, A. S., Puchkin, I. A., Yashunsky, D. V., Antonets, A. V., Kutsevalova, O. Y., & Nifantiev, N. E. (2021) · Journal of Fungi · doi:10.3390/jof7070504 · Cited by 23
“Invasive candidiasis (IC) affects about 750,000 people worldwide with a case fatality rate of ~30–55% [1].”
BackgroundLópez‐Berges, M. S., Scheven, M. T., Hortschansky, P., Misslinger, M., Baldin, C., Gsaller, F., Werner, E. R., Krüger, T., Kniemeyer, O., Weber, J., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147739 · Cited by 21
“with estimated 3,000,000 cases of chronic pulmonary aspergillosis and 250,000 cases of lifethreatening invasive aspergillosis worldwide [3,4].”
BackgroundMoirangthem, R., Kumar, K., & Kaur, R. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02415-20 · Cited by 20
Kumaresan, P. R., Wurster, S., Bavisi, K., da Silva, T. A., Hauser, P. J., Kinnitt, J., Albert, N. D., Bharadwaj, U., Neelapu, S. S., & Kontoyiannis, D. P. (2024) · mBio · doi:10.1128/mbio.03413-23 · Cited by 23
“I nvasive fungal infections pose a significant threat to human life and are responsible for about 1.5 million deaths each year (1).”
BackgroundInfluentialUtilizing Next-Generation Sequencing: Advancements in the Diagnosis of Fungal Infections
Naik, S., Kashyap, D., Deep, J., Darwish, S., Cross, J., Mansoor, E., Garg, V. K., & Honnavar, P. (2024) · Diagnostics · doi:10.3390/diagnostics14151664 · Cited by 28
“As per the Global Action Fund for fungal infections (GAFFI-https://gaffi.org/, accessed on 4 June 2024), over 300 million individuals worldwide suffer from serious fungal infections, resulting in over 1.5 million deaths yearly [2].”
BackgroundInfluentialZhao, J., Zhuge, R., Hu, B., et al. (2025) · Infection · doi:10.1007/s15010-025-02520-0 · Cited by 20
“Although the epidemiology of fungal diseases has greatly changed over the last few decades, these infections continue to predominantly affect immunocompromised patients [37].”
Lee, A., Wang, N., Carter, C. L., Zimmerman, M., Dartois, V. A., Shaw, K. J., Perlin, D. S., & Zhao, Y. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02476-20 · Cited by 21
“mated at 750,000 cases annually (3), with an associated crude mortality rate in excess”
BackgroundGündüz, M. G., Kaya, B., Özkul, C., Şahın, O., Rekha, E. M., Sriram, D., & Ülküseven, B. (2021) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2021.130674 · Cited by 21
Shlezinger, N., & Hohl, T. M. (2021) · mSphere · doi:10.1128/msphere.00260-21 · Cited by 20
“NADPH oxidase enzyme on the phagosomal membrane (7, 9).”
BackgroundPanagopoulou, P., & Roilides, E. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1996562 · Cited by 24
Gobeil, S., Bobay, B. G., Juvvadi, P. R., Cole, D. C., Heitman, J., Steinbach, W. J., Venters, R. A., & Spicer, L. D. (2021) · mBio · doi:10.1128/mbio.03000-21 · Cited by 22
“More than 1.6 million people die annually of infections caused by the major fungal pathogenic species of Aspergillus, Candida, Cryptococcus, and Mucorales (1).”
BackgroundInfluentialPfaller, M. A., Carvalhaes, C. G., DeVries, S. D., Huband, M. D., & Castanheira, M. (2021) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2021.115627 · Cited by 22
Evaluation of 2-[18F]-Fluorodeoxysorbitol PET Imaging in Preclinical Models of Aspergillus Infection
Lai, J., Shah, S., Knight, R., Martínez‐Orengo, N., Patel, R., Mitchell, A. L., Wang, Z., Basuli, F., Ordoñez, A. A., Jain, S. K., et al. (2021) · Journal of Fungi · doi:10.3390/jof8010025 · Cited by 20
Eradication of Fungi Using MoSe2/Chitosan Nanosheets
Saha, S., Gilliam, M. S., Wang, Q. H., & Green, A. A. (2022) · ACS Applied Nano Materials · doi:10.1021/acsanm.1c01013 · Cited by 20
Silva, V. K. A., Bhattacharya, S., Oliveira, N. K., Savitt, A. G., Zamith‐Miranda, D., Nosanchuk, J. D., & Fries, B. C. (2022) · mBio · doi:10.1128/mbio.00190-22 · Cited by 23
“account for most of the invasive fungal infections (4).”
BackgroundOrtiz, S. C., Pennington, K., Thomson, D. D., & Bertuzzi, M. (2022) · Journal of Fungi · doi:10.3390/jof8030264 · Cited by 31
“Aspergillus fumigatus spores are a major component of airborne particulate matter (1–100/m3) [1] and initiate more than 3,000,000 chronic and 300,000 invasive diseases per annum, globally [2,3].”
BackgroundFeurstein, C., Meyer, V., & Jung, S. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.812903 · Cited by 20
Dougue, A. N., El‐Kholy, M. A., Giuffrè, L., Galeano, G., D′Aleo, F., Kountchou, C. L., Nangwat, C., Dzoyem, J. P., Giosa, D., Pernice, I., et al. (2022) · Mycoses · doi:10.1111/myc.13483 · Cited by 20
A lateral flow assay for the immunodiagnosis of human cat‐transmitted sporotrichosis
Cognialli, R. C. R., Bloss, K., dos Santos-Weiss, I. C. R., et al. (2022) · Mycoses · doi:10.1111/myc.13516 · Cited by 20
Inactivation of the Complement Lectin Pathway by Candida tropicalis Secreted Aspartyl Protease-1
Valand, N., Brunt, E., Gazioglu, O., Yeşilkaya, H., Mitchell, D. A., Horley, N., Arroo, R., Kishore, U., Wallis, R., & Girija, U. V. (2022) · Immunobiology · doi:10.1016/j.imbio.2022.152263 · Cited by 24
Bioactive peptides from scorpion venoms: therapeutic scaffolds and pharmacological tools
Kamau, P. M., Zhong, J., Yao, B., Lai, R., & Luo, L. (2023) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(23)60382-6 · Cited by 30
Tang, N., Yuan, S., Luo, Y., Wang, A.-J., Sun, K., Liu, N., & Tao, K. (2023) · ACS Omega · doi:10.1021/acsomega.2c07740 · Cited by 21
Fungal gut microbiota dysbiosis in systemic lupus erythematosus
Yang, P., Xu, R. C., Chen, F., Chen, S., Khan, A., Li, L., Zhang, X., Wang, Y., Xu, Z., & Shen, H. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1149311 · Cited by 21
Lima, W. G., Brito, J. C. M., Verly, R. M., & de Lima, M. E. (2024) · Toxins · doi:10.3390/toxins16010024 · Cited by 21
“In addition, it is estimated that fungal diseases affect more than one billion people worldwide, of whom more than 300 million people suffer from severe fungal infections each year, resulting in 1.5 million deaths [74,75].”
BackgroundInfluentialInsight to the antifungal properties of Amaryllidaceae constituents
Nair, J. J., & Staden, J. V. (2018) · Phytomedicine · doi:10.1016/j.phymed.2018.11.013 · Cited by 27
8-Hydroxyquinoline 1,2,3-triazole derivatives with promising and selective antifungal activity
da Silva, N. M., Gentz, C. D. B., Reginatto, P., Fernandes, T. H. M., Kaminski, T. F. A., Lopes, W., Quatrin, P. M., Vainstein, M. H., Abegg, M. A., Lopes, M. S., et al. (2020) · Medical Mycology · doi:10.1093/mmy/myaa061 · Cited by 20
Targeting Unconventional Pathways in Pursuit of Novel Antifungals
Nguyen, S. A., Truong, J. Q., & Bruning, J. B. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.621366 · Cited by 23
Şahin, F., Çelik, N., Ceylan, A., Ruzi, M., & Önses, M. S. (2022) · ACS Omega · doi:10.1021/acsomega.2c02540 · Cited by 21
Machine learning to identify clinically relevant Candida yeast species
Shankarnarayan, S. A., & Charlebois, D. A. (2023) · Medical Mycology · doi:10.1093/mmy/myad134 · Cited by 30
Cirstea, N., Radu, A.-F., Vesa, C. M., Radu, A. F., Bungău, A. F., Ţiţ, D. M., Nistor-Cseppento, C. D., Tarce, A. G., & BUNGAU, S. G. (2024) · Cureus · doi:10.7759/cureus.69764 · Cited by 31
Pruitt, H. M., Zhu, J., Riley, S. P., & Shi, M. (2025) · Journal of Fungi · doi:10.3390/jof11030236 · Cited by 26
“Infections caused by biofilm-associated fungal pathogens, particularly Cryptococcus , Candida , and Aspergillus species, are estimated to cause over one million deaths annually, emphasizing the urgent need for a deeper understanding of biofilm-associated pathogenesis [39].”
Mallick, D. C., Kaushik, N., Goyal, L., Mallick, L., & Singh, P. K. (2025) · Diseases · doi:10.3390/diseases13040093 · Cited by 35
“Prolonged stays in intensive care units further exacerbate this risk as patients are exposed to multiple predisposing factors over extended periods [5].”
Research progress on the drug resistance mechanisms of Candida tropicalis and future solutions
Xiong, H., Zhao, R., Han, S., Liu, Z., Zhang, X., Jia, Z., Cui, J., Zhang, Y., & Wang, X. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1594226 · Cited by 25
Antifungal resistance: Emerging mechanisms and implications (Review)
Kadariswantiningsih, I. N., Empitu, M. A., Santosa, T., & Alimu, Y. (2025) · Molecular Medicine Reports · doi:10.3892/mmr.2025.13612 · Cited by 30
Estarriaga‐Navarro, S., Valls, T., Plano, D., Sanmartín, C., & Goicoechea, N. (2025) · Antioxidants · doi:10.3390/antiox14080942 · Cited by 31
“Some fungal diseases are acute and severe, such as cryptococcal meningitis; others are recurrent, such as candida vaginitis or oral candidiasis in acquired immunodeficiency syndrome; and others become chronic, such as pulmonary aspergillosis or tinea capitis [60,61].”
Vijayalakshmi, K., Swaramanjari, T., Shanmugavel, M., & Gnanamani, A. (2025) · Discover Biotechnology · doi:10.1007/s44340-025-00024-z · Cited by 28
“More than 1.6 million people die from fungal illnesses each year, a statistic that is roughly three times higher than estimates for mortality from malaria and comparable to those from tuberculosis [38].”
InfluentialRevilla‐Guarinos, A., Dürr, F., Popp, P. F., Döring, M., & Mascher, T. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.02022 · Cited by 21
Reactive oxygen mediated apoptosis as a therapeutic approach against opportunistic Candida albicans
Atriwal, T., Chawla, M., Hussain, A., Alajmi, M. F., & Abid, M. (2021) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2020.12.004 · Cited by 19
Ong, J. Y., Swidah, R., Monti, M., Schindler, D., Dai, J., & Cai, Y. (2021) · Bioengineering · doi:10.3390/bioengineering8030042 · Cited by 20
“5 million and affect over a billion of people every year [11].”
BackgroundVaccine-Induced Protection in Two Murine Models of Invasive Pulmonary Aspergillosis
Rayens, E. A., Rabacal, W., Kang, S., Celia-Sanchez, B. N., Momany, M., & Norris, K. A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.670578 · Cited by 21
“Globally, Aspergillus infections are estimated to affect over 3 million people and contribute to nearly 500,000 deaths per year (1, 2).”
BackgroundPekmezovic, M. G., Krušić, M. K., Malagurski, I., Milovanović, J., Stępień, K., Guzik, M. W., Charifou, R., Babu, R. P., O’Connor, K. E., & Nikodinović‐Runić, J. (2021) · Antibiotics · doi:10.3390/antibiotics10060737 · Cited by 21
“Fungal infections, usually caused by opportunistic pathogens, affect nearly a billion people worldwide [21].”
BackgroundGarcía, R., Itto‐Nakama, K., Rodríguez-Peña, J. M., Chen, X., Sanz, A. B., de Lorenzo, A., Pavón‐Vergés, M., Kubo, K., Ohnuki, S., Nombela, C., et al. (2021) · The FASEB Journal · doi:10.1096/fj.202100278r · Cited by 24
Misslinger, M., Petřík, M., Pfister, J., Hubmann, I., Bendová, K. D., Decristoforo, C., & Haas, H. (2021) · Journal of Fungi · doi:10.3390/jof7090734 · Cited by 19
“Due to insufficient diagnoses, immunocompromised patients are often subject to empirical therapy with azoles, the main antifungal therapy [1,2].”
BackgroundDC-SIGN targets amphotericin B-loaded liposomes to diverse pathogenic fungi
Ambati, S., Pham, T., Lewis, Z., Lin, X., & Meagher, R. B. (2021) · Fungal Biology and Biotechnology · doi:10.1186/s40694-021-00126-3 · Cited by 20
“, cause a majority of global life-threatening invasive fungal infections and hundreds of thousands of deaths annually [19, 20].”
BackgroundMyers, A. N., Lawhon, S. D., Diesel, A. B., Bradley, C. W., Hoffmann, A. R., & Murphy, W. J. (2022) · PLoS Genetics · doi:10.1371/journal.pgen.1010062 · Cited by 23
Černáková, L., Líšková, A., Lengyelová, L., & Rodrigues, C. F. (2022) · Medicina · doi:10.3390/medicina58050576 · Cited by 29
“thrush) annually, which, with skin, hair, and nail fungal infections, is the highest among fungi diseases [5].”
BackgroundExploring a novel genomic safe-haven site in the human pathogenic mould Aspergillus fumigatus
Furukawa, T., van Rhijn, N., Chown, H., Rhodes, J. L., Alfuraiji, N., Fortune‐Grant, R., Bignell, E., Fisher, M. C., & Bromley, M. (2022) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2022.103702 · Cited by 17
“Worldwide, infections caused by this cosmopolitan fungus lead to in excess of 600,000 deaths every year (Bongomin et al. 2017) and our ability to treat these infections remains critically challenged as there are limited treatment options.”
Bravo-Chaucanés, C. P., Vargas‐Casanova, Y., Chitiva, L. C., Ceballos-Garzón, A., Costa, G. M., & Parra‐Giraldo, C. M. (2022) · Journal of Fungi · doi:10.3390/jof8080784 · Cited by 25
“5 million people yearly, similar to mortality rates due to tuberculosis and about three times more than malaria [68].”
BackgroundInterpretation, pitfalls of biomarkers in diagnosis of invasive fungal diseases
Lass‐Flörl, C., Alastruey‐Izquierdo, A., Gupta, R., & Chakroborti, A. (2022) · Indian Journal of Medical Microbiology · doi:10.1016/j.ijmmb.2022.07.013 · Cited by 22
Borba-Santos, L. P., Rollin‐Pinheiro, R., Fontes, Y. D. S., dos Santos, G. M. P., Araújo, G. R. D. S., Rodrigues, A. M., Guimaraes, A. J., de Souza, W., Frasés, S., Ferreira‐Pereira, A., et al. (2022) · Journal of Fungi · doi:10.3390/jof8101004 · Cited by 20
“The increasing incidence of fungal infections highlighted the need to find new treatment alternatives [1].”
BackgroundSerological evidence of chronic pulmonary Aspergillosis in tuberculosis patients in Kenya
Mohamed, A., Obanda, B. A., Njeri, H. K., Loroyokie, S. N., Mashedi, O., Ouko, T. T., Gatumwa, E. M., Korir, R. K., Yaguchi, T., & Bii, C. C. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07782-9 · Cited by 25
“Chronic Pulmonary Aspergillosis is a well-established complication of PTB [5, 8, 9, 26, 27].”
BackgroundInfluentialKanj, S. S., Omrani, A. S., Al-Abdely, H. M., Subhi, A. F., Fakih, R. O. E., Abosoudah, I. F., Kanj, H., & Dimοpoulos, G. (2022) · Journal of Fungi · doi:10.3390/jof8111146 · Cited by 21
“Invasive candidiasis (IC) is the most prevalent IFI worldwide, followed by invasive aspergillosis (IA) with about 700,000 cases and 250,000 confirmed annual cases, respectively [3,4].”
BackgroundInfluentialLipase-Responsive Amphotericin B Loaded PCL Nanoparticles for Antifungal Therapies
Uroro, E. O., Bright, R., Hayles, A., & Vasilev, K. A. (2022) · Nanomaterials · doi:10.3390/nano13010155 · Cited by 24
Systemic Antifungal Therapy for Invasive Pulmonary Infections
Ben‐Ami, R. (2023) · Journal of Fungi · doi:10.3390/jof9020144 · Cited by 30
“Human invasive fungal diseases (IFDs) have increased in frequency and diversity over the past three decades [1,2], driven by an ever-expanding population of immunecompromised patients and the increasingly appreciated effects of climate change [3,4].”
BackgroundCruz, R., & Wuest, W. M. (2023) · Tetrahedron · doi:10.1016/j.tet.2023.133268 · Cited by 19
Ibrahim, A. G., Elgammal, W. E., Hashem, A. H., Mohamed, A. E., Awad, M. A., & Hassan, S. M. (2023) · Polymer Bulletin · doi:10.1007/s00289-023-04765-x · Cited by 19
“Over 300,000, 750,000, and 10,000 cases, respectively, of invasive aspergillosis, candidiasis, and mucormycosis have been reported in recent years [4].”
Du, C., Yang, X., Long, Y., Lang, X., Liu, L., Xu, Y., Wu, H., Chu, Y., Hu, X., Deng, J., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115388 · Cited by 20
Kashyap, V. H., Mishra, A., Bordoloi, S., Varma, A. K., & Joshi, N. C. (2023) · Mycoses · doi:10.1111/myc.13619 · Cited by 24
Panfungal PCR on formalin-fixed, paraffin-embedded tissue: to proceed or not proceed?
Sparks, R., Halliday, C. L., Green, W., et al. (2023) · Pathology · doi:10.1016/j.pathol.2023.03.011 · Cited by 19
Cornely, O. A., Ostermann, H., Koehler, P. A., Teschner, D., Limburg, E., Kramer, W. G., Barbat, S. H., Tawadrous, M., & Hodges, M. R. (2023) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkad269 · Cited by 21
Lee, C. K., Oliveira, L. V. N., Akalin, A., Specht, C. A., Lourenco, D., Gomez, C. L., Ramirez‐Ortiz, Z. G., Wang, J. P., & Levitz, S. M. (2023) · mBio · doi:10.1128/mbio.01633-23 · Cited by 21
“Worldwide, >200,000 people/year are estimated to develop invasive aspergillosis (4, 5).”
BackgroundGregor, J. B., Gutierrez-Schultz, V. A., Hoda, S., Baker, K. M., Saha, D., Burghaze, M. G., Vazquez, C., Burgei, K. E., & Briggs, S. D. (2023) · mSphere · doi:10.1128/msphere.00311-23 · Cited by 25
“F ungal infections pose a significant public health concern, with over a billion superficial infections and 1.5 million deaths, mostly from invasive infections, occurring annually worldwide (1, 2).”
BackgroundInfluentialZeng, M., Zhou, X., Yang, C., Liu, Y., Zhang, J., Xin, C., Qin, G., Liu, F., & Song, Z. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1253197 · Cited by 23
“Recent global estimates have shown that aspergillosis accounts for about 5 million cases of ABPA (Agarwal et al., 2020), 3 million cases of CPA, and one-quarter million cases of IA annually (Bongomin et al., 2017).”
Emri, T., Antal, K., Varga, K. E., Gila, B. C., & Pócsi, I. (2024) · Journal of Fungi · doi:10.3390/jof10030221 · Cited by 21
“Invasive aspergillosis, as the most life threatening systemic infection frequently caused by A. fumigatus , annually affects more than 250,000 people worldwide [1].”
BackgroundThe Impact of Climate Change on Human Fungal Pathogen Distribution and Disease Incidence
Hamm, P. S., & Torres-Cruz, T. J. (2024) · Current Clinical Microbiology Reports · doi:10.1007/s40588-024-00224-x · Cited by 28
“Fungal diseases kill more than 1.5 million and affect over a billion people per year [8].”
InfluentialFranconi, I., Rizzato, C., Ghelardi, E., & Lupetti, A. (2024) · BMC Microbiology · doi:10.1186/s12866-024-03267-8 · Cited by 21
“It has been estimated that Aspergillus invasive infections affect more than 300.000 subjects worldwide per year and are associated with high mortality rates ranging from 45 to 99% [13].”
BackgroundInfluentialMeneghello, S., Bernabé, G., Pietra, G. D., Sopra, S. D., Vecchio, C. D., Cattelan, A. M., Castagliuolo, I., & Brun, P. (2024) · Journal of Fungi · doi:10.3390/jof10100707 · Cited by 25
“However, Candida spp. can become pathogenic, causing various infections in both immunocompetent and immunocompromised subjects [3,4].”
BackgroundResultInfluentialEstimated Burden of Serious Fungal Diseases in Serbia
Arsić-Arsenijević, V. S., & Denning, D. W. (2018) · Journal of Fungi · doi:10.3390/jof4030076 · Cited by 22
“Generally, SFD usually occur in defined high-risk populations (HRP) such as low-birth-weight infants and severely immunocompromised hematological or transplant patients [1], although lung disease is a common antecedent also.”
BackgroundSelf-citationKrishnan, R., Pant, T., Sankaranarayan, S., Stenberg, J., Jain, R. D., & Dandekar, P. P. (2018) · Materials Science and Engineering C · doi:10.1016/j.msec.2018.08.016 · Cited by 20
From the Clinical Mycology Laboratory: New Species and Changes in Fungal Taxonomy and Nomenclature
Wiederhold, N. P., & Gibas, C. F. C. (2018) · Journal of Fungi · doi:10.3390/jof4040138 · Cited by 20
“Infections caused by fungi are highly prevalent in humans, as it is estimated that greater than 1 billion people worldwide have infections caused by these organisms [1,2].”
BackgroundProtein-Protein Interactions in Candida albicans
Schoeters, F., & Dijck, P. V. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.01792 · Cited by 21
Messer, S. A., Carvalhaes, C. G., Castanheira, M., & Pfaller, M. A. (2020) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2020.115007 · Cited by 21
Madan, T., & Kishore, U. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00229 · Cited by 19
“With more than a billion people with mild infections, several millions mucosal candidiasis cases and 150 million people with serious fungal diseases, fungi have a huge impact on public health (Bongomin et al., 2017).”
BackgroundBeswick, E., Amich, J., & Gago, S. (2020) · Pathogens · doi:10.3390/pathogens9080639 · Cited by 20
Self-citationNatural Variation in Clinical Isolates of Candida albicans Modulates Neutrophil Responses
Shankar, M., Lo, T. L., & Traven, A. (2020) · mSphere · doi:10.1128/msphere.00501-20 · Cited by 21
“Fungal infections are a global health care problem affecting countries around the world (1, 2).”
BackgroundNew Insights on Mucormycosis and Its Association With the COVID-19 Pandemic
Alshahawey, M., El-Housseiny, G. S., Elsayed, N. S., Alshahrani, M. Y., Wakeel, L. M. E., & Aboshanab, K. M. (2021) · Future Science OA · doi:10.2144/fsoa-2021-0122 · Cited by 21
“910,000 cases globally if India is included in the data [52,53].”
BackgroundTargeted Delivery of Antifungal Liposomes to Rhizopus delemar
Choudhury, Q. J., Ambati, S., Lewis, Z., & Meagher, R. B. (2022) · Journal of Fungi · doi:10.3390/jof8040352 · Cited by 20
“Globally, there are approximately 900,000 individuals with mucormycosis, mostly in India [1,2].”
BackgroundSircar, G., Bhowmik, M., Sarkar, R. K., Najafi, N., Dasgupta, A., Focke‐Tejkl, M., Flicker, S., Mittermann, I., Valenta, R., Bhattacharya, K., et al. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.011659 · Cited by 20
Queiroz‐Telles, F., Bonifáz, A., Rossow, J. A., & Chindamporn, A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818731-9.00046-x · Cited by 26
Esmaeili, A., Saleh, I., & Abu‐Dieyeh, M. H. (2025) · Phytochemistry Reviews · doi:10.1007/s11101-025-10093-x · Cited by 38
“Fungal infections are accountable for about 1.7 million deaths each year, comparable to the mortality rate of tuberculosis (1.5 million deaths per year) and significantly higher than that of malaria (405,000 deaths per year) (Bongomin et al. 2017; WHO 2023; WHO 2020).”
InfluentialCandidalysin biology and activation of host cells
Lortal, L., Lyon, C. M., Sprague, J. L., Sonnberger, J., Paulin, O. K. A., Wickramasinghe, D. N., Richardson, J. P., Hube, B., & Naglik, J. R. (2025) · mBio · doi:10.1128/mbio.00603-24 · Cited by 24
Johnson, C., Chen, B., Bhalla, A., Crowell, E. L., & Zhang, F. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125822 · Cited by 19
Choudhary, H., Singh, S., Singh, R., Agarwal, R., Kaur, H., Ghosh, A. K., Chakrabarti, A., & Rudramurthy, S. M. (2021) · Mycopathologia · doi:10.1007/s11046-020-00514-0 · Cited by 19
Analysis of Antimicrobial Properties of PVA-Based Coatings with Silver and Zinc Oxide Nanoparticles
Pulit‐Prociak, J., Staroń, A., Prokopowicz, M., Magielska, K., & Banach, M. (2021) · Journal of Inorganic and Organometallic Polymers and Materials · doi:10.1007/s10904-020-01838-6 · Cited by 20
“5 million to over a billion people are killed by diseases caused by fungi [1].”
BackgroundGisi, U. (2021) · Plant Pathology · doi:10.1111/ppa.13429 · Cited by 26
Rollin‐Pinheiro, R., Bayona-Pacheco, B. L., Domingos, L. T. S., Curvelo, J. A. D. R., de Castro, G. M. M., Barreto‐Bergter, E., & Ferreira‐Pereira, A. (2021) · Pathogens · doi:10.3390/pathogens10070856 · Cited by 18
Ortiz, S. C., Huang, M., & Hull, C. M. (2021) · mBio · doi:10.1128/mbio.01672-21 · Cited by 20
“5 million deaths a year worldwide (1).”
Genetic Diversity and Dispersal of Aspergillus fumigatus in Arctic Soils
Korfanty, G. A., Dixon, M., Jia, H., Yoell, H., & Xu, J. (2021) · Genes · doi:10.3390/genes13010019 · Cited by 22
“Invasive aspergillosis, the most severe form of aspergillosis, is estimated to occur at over 200,000 cases annually worldwide [6].”
BackgroundHusain, F., Pathak, P., Román, E., Plá, J., & Panwar, S. L. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.794855 · Cited by 20
Mendonça, A. M. S., Monteiro, C. D. A., Neto, R. N. M., Monteiro, A. S., Mondêgo‐Oliveira, R., Nascimento, C. E. C., da Silva, L. C. N., Neto, L. G. L., Carvalho, R. C., & de Sousa, E. M. (2022) · Antibiotics · doi:10.3390/antibiotics11020265 · Cited by 22
Das, T., Joseph, J., Jakati, S., Sharma, S., Velpandian, T., Padhy, S. K., Das, V. A., Shivaji, S., Nayak, S., Behera, U. C., et al. (2022) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_2329_21 · Cited by 20
“Life‐threatening fungal diseases such as invasive Aspergillus and Candida infections are associated with high mortality.[60,61] In addition, indiscriminate use of antifungal agents and widespread agricultural antifungal exposure have resulted in the spread of resistant fungal pathogens for one or more antifungal drugs.”
BackgroundWen, S.-R., Yang, Z.-H., Dong, T.-X., Li, Y., Cao, Y.-K., Kuang, Y., & Li, H.-B. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.842434 · Cited by 20
“5million people die from fungal infections worldwide each year, which is similar to the number of deaths caused by tuberculosis each year (16).”
BackgroundSalazar, S. B., Pinheiro, M. J. F., Sotti-Novais, D., Soares, A. R., Lopes, M. M., Ferreira, T., Rodrigues, V., Fernandes, F., & Mira, N. P. (2022) · G3 Genes Genomes Genetics · doi:10.1093/g3journal/jkac110 · Cited by 20
Novel avenues for identification of new antifungal drugs and current challenges
Jampílek, J. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.2097659 · Cited by 21
Mourer, T., Ghalid, M. E., Pehau‐Arnaudet, G., Kauffmann, B., Loquet, A., Brûlé, S., Cabral, V., d’Enfert, C., & Bachellier‐Bassi, S. (2023) · npj Biofilms and Microbiomes · doi:10.1038/s41522-023-00371-x · Cited by 32
“Recent epidemiological surveys have reported that invasive candidiasis accounts for 75% of all invasive fungal infections 5 – 7 and Candida species are now recurrently found among the fi ve leading causes of healthcare-associated bloodstream infections 8 – 10 .”
Background
Metadata
- Authors
- Bongomin, F., Gago, S., Oladele, R., & Denning, D.
- Affiliations
- University of Manchester (GB)
- Corresponding author
- Denning, David
- Venue
- Journal of Fungi
- Publisher
- MDPI AG
- Published
- 2017-10-18
- Volume
- 3
- Issue
- 4
- Pages
- 57
- ISSN
- 2309-608X (ISSN-L)
- PMC
- PMC5753159
- OpenAlex
- W2767031614
- Semantic Scholar
- a31bc4c8c2356520b0818d41b5c4a2e2091b6f32
- Cited by
- 2,953
- References
- 192
- Citations by year
- 2026: 280 · 2025: 388 · 2024: 518 · 2023: 436 · 2022: 427 · 2021: 370 · 2020: 307 · 2019: 156 · 2018: 67 · 2017: 2
- FWCI
- 22.27
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Fungi (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC/P002390/1)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Health Sciences › Medicine › Dermatology › Nail Diseases and Treatments
- Keywords
- fungal infection, disease burden estimation, prevalence, chronic pulmonary aspergillosis, cryptococcal meningitis, invasive candidiasis, Pneumocystis carinii pneumonia, invasive aspergillosis, disseminated histoplasmosis, fungal asthma, fungal keratitis, HIV/AIDS, antifungal therapy, estimation accuracy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.